We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Automated Immunoassay for Testosterone Evaluated

By LabMedica International staff writers
Posted on 21 Feb 2011
A new electrochemiluminescence testosterone immunoassay has been evaluated and compared with existing methods. More...


The competitive immunoassay uses high affinity sheep monoclonal testosterone-specific antibody, which is complexed with the serum samples, and after processing the chemiluminescent emissions are measured by a photomultiplier.

Scientists at the University Medical Center Göttingen, (German), collaborated with others medical centers to evaluate the second-generation electrochemiluminescence assay and compare it to a validated assay. The scientists investigated the within-run precision, total precision, and method comparisons to the former immunoassay and the liquid chromatography tandem mass spectrometry (LC-MS/MS) assay. They were also interested in establishing reference intervals for adults and children. Special attention was paid to females with acute renal failure.

The within-run precision and total precision were determined using five different and site-specific human serum pools and two quality control samples. The within-run imprecision ranged from 12.8 μg/L, (0.9%) to 0.23 μg/L (5.2%), and total imprecision ranged from 12.7 μg/L (2.2%) to 0.22 μg/L (8.5%). The recovery according to quality control sample target values was 2.51 μg/L (95.4%) at one center, and 6.30 μg/L (103.6%) at another.

The new Elecsys Testo II assay (Roche Diagnostics GmbH, Mannheim, Germany) was compared against the former Roche Elecsys Testo assay and to a validated LC-MS/MS assay. Precision was improved especially at concentrations below 2.0 μg/L when compared to the former Elecsys Testo assay. The measuring range of 0.12 μg/L to 15.0 μg/L fulfils clinical needs. The new Elecsys Testo II assay demonstrated superior agreement in comparison to the validated LC-MS/MS method indicating an improved specificity.

Surprisingly, some high testosterone concentrations were found in samples from female patients, as confirmed by LC-MS/MS, as these individuals were suffering from polycystic ovary (PCO) syndrome or even androgen-producing tumors. The authors noted that overestimated values, especially with the former Elecsys immunoassay as compared to LC-MS/MS, were found to be from patients suffering from end-stage renal disease undergoing hemodialysis. The study was published in February 2011, in Clinical Biochemistry.

Related Links:
University Medical Center Göttingen
Roche Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.